The largest meta-analysis of GLP-1 cardiovascular outcomes ever assembled landed May 21 in Cardiovascular Diabetology -- Endocrinology Reports. Researchers at Anglia Ruskin University pooled 11 randomized controlled trials covering 91,490 patients and found that GLP-1 receptor agonists reduced major adverse cardiovascular events by approximately 13% versus placebo over an average of 2.7 years. Heart attack, stroke, cardiovascular death, heart failure hospitalization, and all-cause mortality all moved in the right direction.
Research-context information only. Peptides and pharmaceuticals discussed below are research compounds or prescription drugs. Protocols, doses, and outcomes reported come from published research. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This is not a single trial. It is the cumulative verdict of a decade of cardiovascular outcome trials spanning semaglutide, liraglutide, dulaglutide, and other GLP-1 agonists. And the practical question it sharpens is straightforward: if you are already sourcing a GLP-1 for weight management, the cardiovascular benefit is no longer speculative -- it is the most replicated signal in modern metabolic pharmacology.
What the Meta-Analysis Found
Dr. Simon Cork's team at Anglia Ruskin set strict inclusion criteria: only randomized, placebo-controlled cardiovascular outcome trials with at least 3,000 participants and a minimum 12-month follow-up. That filter yielded 11 qualifying trials and 91,490 total subjects.
The headline: a ~13% reduction in 3-point MACE (cardiovascular death, non-fatal heart attack, non-fatal stroke) across the GLP-1 class compared to placebo.
Secondary outcomes tracked the same direction:
- Cardiovascular mortality -- significant reduction
- Non-fatal myocardial infarction -- significant reduction
- Non-fatal stroke -- significant reduction
- Heart failure hospitalization -- significant reduction
- All-cause mortality -- significant reduction
"These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes," Dr. Cork stated. The benefits were "consistent across different drugs, trial designs and patient groups."
The 11 trials included the landmark studies that defined this drug class: LEADER (liraglutide), SUSTAIN-6 and SELECT (semaglutide), REWIND (dulaglutide), HARMONY Outcomes (albiglutide), and EXSCEL (exenatide), among others. The average follow-up of 2.7 years is significant -- longer-duration data strengthens the causal inference beyond what any single 52-week trial can provide.
Which GLP-1 Offers the Most Cardiovascular Protection?
Not all GLP-1 receptor agonists are created equal on heart outcomes. The meta-analysis confirms a class-wide signal, but individual trial data reveals meaningful differences.
Semaglutide leads. The SELECT trial (semaglutide 2.4 mg in patients with obesity and established CVD but without diabetes) demonstrated a 20% MACE reduction -- the first time any GLP-1 proved cardiovascular benefit in a non-diabetic population. SUSTAIN-6 earlier showed a 26% reduction in 3-point MACE in type 2 diabetes, driven primarily by stroke reduction.
Liraglutide is the second-strongest. LEADER showed a 13% MACE reduction and, uniquely, a significant reduction in all-cause mortality -- a hard endpoint most cardiovascular trials fail to move.
Dulaglutide is proven but modest. REWIND showed a 12% reduction in MACE in a broader type 2 diabetes population with lower baseline cardiovascular risk.
Tirzepatide's position is unclear. SURPASS-CVOT showed non-inferiority to dulaglutide (not placebo), meaning tirzepatide has demonstrated it is not worse than an active comparator, but does not yet have a placebo-controlled cardiovascular outcome trial proving superiority. This matters for buyers who are choosing between semaglutide and tirzepatide: tirzepatide wins on raw weight loss (EASO's May 2026 algorithm update placed tirzepatide above semaglutide for body-weight management), but semaglutide has the stronger cardiovascular evidence base.
Retatrutide has no cardiovascular outcome data yet. The TRIUMPH cardiovascular readouts are not expected until 2027--2028. Retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) may or may not replicate the cardiovascular signal. For now, the TRIUMPH-1 Phase 3 data showing 30.3% weight loss positions it as the most potent weight-loss agent in development, but heart protection remains unproven.
What This Means for Buyers
The practical calculus sharpens:
If cardiovascular risk is your primary concern (prior heart attack, stroke, peripheral artery disease, or strong family history), semaglutide has the most data and the largest effect size. The real-world STEER cohort also showed a 29% MACE reduction versus tirzepatide in non-diabetic obesity with established CVD.
If maximum weight loss is the priority and cardiovascular risk is secondary, tirzepatide or retatrutide deliver more kilos lost. But the meta-analysis makes clear that any GLP-1 provides meaningful heart protection -- the 13% class-wide effect is not concentrated in one drug.
If you are sourcing compounded or research-grade GLP-1, the cardiovascular benefit documented in these trials used pharmaceutical-grade formulations. Third-party COA testing from your vendor is the closest proxy for potency assurance in the research market. Vendors with published purity reports and batch-level COAs offer the highest confidence that what you are injecting matches the trial formulations.
Research-grade semaglutide and liraglutide remain available from recommended vendors. Compare current pricing and stock at /best/semaglutide and /peptides/liraglutide. For current deals across all recommended vendors, see the deals page.
